The Mechanism of Action of SAR302503
Tal Zaks, MD, PhD, explains the mechanism of action of SAR302503, a TKI being investigated in a phase III trial in patients with intermediate-2 or high-risk myelofibrosis.
Tal Zaks, MD, PhD, vice president and head of development at Sanofi Oncology, explains the mechanism of action of SAR302503, a tyrosine kinase inhibitor being investigated in a phase III trial in patients with intermediate-2 or high-risk myelofibrosis.
Zaks explains that when a mutation in the JAK/STAT pathway is present, JAK2 is hyperactivated, causing abnormal intracellular signaling and abnormal blood proliferation and production. SAR302503 inhibits enzymatic activity and blocks abnormal signaling.
Clinical Pearls
When testing a patient's blood, Zaks says, it becomes evident where the signaling pathway is hyperactivated and where the drug blocks signaling. It is this link between the molecular rational design of the drug that will inhibit the pathway and culminate in the clinical benefit of symptom amelioration. Zaks hopes, in the long run, that there will be a change in the pathophysiology of this disease so that patients feel better and the drug reverts the disease process so that patients can live longer.
- SAR302503 is being investigated in a phase III trial in patients with intermediate-2 or high-risk myelofibrosis
- SAR302503 is a TKI that inhibits enzymatic activity, blocking abnormal signaling
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
